Shenzhen Raysightmed Co., Ltd. (hereinafter referred to as “RaysightMed”) recently announced the completion of a new round of strategic financing amounting to nearly RMB 100 million. The investment was jointly made by Haihe Industry Fund and Zhongli Fund, representing state-owned industrial capital at both municipal and district levels in Tianjin. The project has officially been established in Tianjin.
It is reported that this round of funding will comprehensively accelerate the industrial scale-up of the company’s entire product portfolio and the large-scale market promotion in Northern China. Leveraging this financing, RaysightMed will establish a standardized mass-production base for high-end medical devices in Tianjin and set up a regional marketing center, forming a dual-drive model of “production capacity + market presence.” This strategy aims to extensively cover the core healthcare markets in North, Northeast, and Northwest China, providing robust support for the rapid volume growth of approved products.
RaysightMed, established in 2017, focuses primarily on the field of precision diagnosis and treatment of cardiovascular diseases. By integrating cutting-edge technologies such as artificial intelligence, hemodynamic simulation, and surgical robotics, it has built an integrated intelligent diagnostic and therapeutic platform covering clinical scenarios including coronary intervention, electrophysiology, and structural heart disease.
Public information reveals that the three co-founders of RaysightMed possess complementary backgrounds, forming a "golden trio" of physics-based simulation, AI, and robotics. CEO Zheng Lingxiao (B.S. from Beihang University, Ph.D. from Johns Hopkins University) specializes in medical physics-based simulation and previously led Dassault Systèmes’ 3D heart modeling project. Chief Scientist Lan Hongzhi (B.S. and M.S. from Tsinghua University, Ph.D. from Duke University) has dedicated over a decade to cardiovascular computational fluid dynamics, hailing from Stanford’s Cardiovascular Simulation Laboratory. CTO Ma Jun (B.S. from Tsinghua University, Ph.D. from Johns Hopkins University) is an expert in AI and surgical robotics, with prior experience at companies such as Intuitive Surgical (da Vinci Surgical System). In 2017, the trio founded RaysightMed in Shenzhen, committed to safeguarding cardiovascular and cerebrovascular health through technological innovation.
It is reported that in this round of financing, the company is prioritizing the advancement of three major product lines: coronary functional assessment, non-invasive coronary evaluation, and intracardiac echocardiography.
In the intraoperative domain, the AngioQFA system provides a one-stop assessment of coronary blood supply and microcirculatory function, and has been routinely adopted in interventional departments. For non-invasive screening, Raysight Fraction (CT-FFR), leveraging AI and hemodynamic simulation, enables ischemia evaluation without invasive procedures, making it suitable for large-scale early screening. Intracardiac Echocardiography (ICE) offers high-definition, real-time imaging support for complex procedures. These three products form a comprehensive portfolio covering intraoperative, preoperative, and intracavitary imaging. The new manufacturing base and the Northern Sales Center will simultaneously enhance production capacity and academic promotion capabilities.
While continuing to deepen its expertise in mature products, RaysightMed has expanded into comprehensive management of chronic cardiovascular diseases. Leveraging core algorithms and clinical data, the company integrates the entire care pathway—pre-hospital screening, in-hospital treatment, and post-hospital follow-up—facilitating a transition from “single-procedure interventions” to “full-cycle health management.” Furthermore, the company has proactively laid out its strategy in AI-driven vascular interventional surgical robots. By integrating large hemodynamic models, real-time image recognition, and intelligent path planning, these systems can autonomously analyze vascular structures, generate optimal strategies, and assist in precise intraoperative operations, thereby lowering the threshold for performing such surgeries and enhancing standardization across procedures.
Leveraging Tianjin’s high-end manufacturing support and clinical resources from Grade A tertiary hospitals, RaysightMed will accelerate product iteration, type testing, and multicenter clinical studies, steadily advancing clinical translation and industrialization. By securing a strategic position in the promising field of intelligent minimally invasive intervention, the company continues to lead innovation in AI-driven precision diagnosis and treatment of cardiovascular diseases.
